VANCOUVER, British Columbia, May 27, 2020 /PRNewswire/ — Bold Therapeutics, a clinical-stage biopharmaceutical company, announced it has executed an option agreement with an undisclosed publicly traded company for exclusive rights to BOLD-100 in South… Read More
Potential for voclosporin to become the first FDA-approved therapy for the treatment of lupus nephritis – NDA Application supported by extensive global clinical program including the pivotal Phase 3 AURORA… Read More
SignalChem, a global leader in cell signaling and protein engineering, has been conducting research on new coronaviruses since the outbreak of the virus. “We understand the importance of accurate and… Read More
Vancouver, BC – May 27, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and… Read More
Ottawa, May 25, 2020 – Innovative Medicines Canada (IMC) today announced the creation of a Research Chair in pandemic preparedness. IMC’s member companies will contribute $500,000 from the IMC COVID-19 Fund… Read More
